Patient Perspectives Shape Liver Cancer Research at UEG Week 2026
The European Liver Patients’ Association emphasizes the importance of patient voices in shaping liver cancer treatment and research at UEG Week 2026.
ELPA announces collaboration with UEG to enhance patient involvement in liver cancer research.
Patient perspectives are crucial for understanding treatment success beyond survival rates.
The initiative aims to improve clinical trials and regulatory decisions through meaningful patient engagement.
At the UEG Week 2026 in Barcelona, the European Liver Patients’ Association (ELPA) announced a significant collaboration with United European Gastroenterology (UEG) to enhance patient involvement in liver cancer research. This partnership includes the establishment of the Patient Representatives Advisory Board (PRAB), which aims to integrate patient perspectives into research, policy, and care over the next three years.
The discussions at the event highlighted the need for a comprehensive understanding of treatment success and quality of life from multiple viewpoints. ELPA emphasized that patients, caregivers, healthcare professionals, and care coordinators often perceive the disease journey differently, and each perspective can uncover vital aspects of treatment burden, independence, and dignity. This multifaceted approach is intended to complement the patient’s voice rather than replace it.
ELPA pointed out that treatment success can vary significantly among individuals. For some, it may mean extended survival, while for others, it could involve reduced suffering or the ability to spend quality time with loved ones. The organization advocates for a shift towards understanding these diverse perspectives earlier in the research process, which can lead to better clinical trial designs and more relevant outcomes.
The implications of this initiative are far-reaching, particularly for individuals living with liver diseases, including liver cancer. By fostering meaningful patient involvement from the outset, the collaboration aims to inform regulatory and health technology assessment (HTA) decisions, ultimately leading to improved patient care and innovative treatment options.
Looking ahead, ELPA is committed to contributing to the UEG PROMs toolkit and engaging in ongoing dialogue with the European Medicines Agency (EMA) and EUHTA. The goal is to ensure that patient perspectives are integrated into clinical development and assessment processes, reinforcing the idea that patient involvement should begin at the research phase and continue throughout the treatment journey.
